ABSTRACT

Introduction: Treatment of osteoporosis with the available drug formulations is still challenging due to multiple associated limitations such as chronic treatment, off-target side effects, poor bone targeting, and low bioavailability. Adopting advanced bone-targeted drug delivery strategies like liposomes is one of the safe and effective approaches for osteoporosis treatment.

Areas covered: This review summarizes the applications of liposomes in gene delivery, bone regeneration, bone-targeted delivery, and as a carrier for drug encapsulation in the treatment of osteoporosis. Details of all the supportive studies are discussed here and the bone-specific roles of the strategies like new generation liposomes in osteoporosis are elaborated. The future scope of performing in-depth research on the bone-targeted liposomes is discussed.

Expert opinion: Liposomes-based bone-targeted delivery of therapeutics seems to be a promising approach for the effective treatment of osteoporosis. But till date, the tremendous in vitro and in vivo research on liposomes has failed to attain significant progress in their clinical translation. From bench to bedside success of the research an interdisciplinary collaboration between the preclinical and clinical experts engaged at different stages of liposomes development is required.

摘要

简介：由于多种相关限制，例如慢性治疗、脱靶副作用、骨靶向性差和生物利用度低，使用可用的药物制剂治疗骨质疏松症仍然具有挑战性。采用脂质体等先进的骨靶向药物递送策略是治疗骨质疏松症的安全有效方法之一。

涵盖领域：这篇综述总结了脂质体在基因传递、骨再生、骨靶向传递以及作为药物包封载体治疗骨质疏松症中的应用。此处讨论了所有支持性研究的详细信息，并详细阐述了新一代脂质体等策略在骨质疏松症中的骨特异性作用。讨论了未来对骨靶向脂质体进行深入研究的范围。

专家意见：基于脂质体的骨靶向治疗似乎是有效治疗骨质疏松症的一种有前途的方法。但迄今为止，对脂质体的大量体外和体内研究未能在其临床转化方面取得重大进展。从研究的台架到床边成功，需要从事脂质体开发不同阶段的临床前和临床专家之间的跨学科合作。